Melanotan II: difference between revisions
Diff·revision 12 → 13·08:36, 11 May 2025
Difference between revision 12 and revision 13 of Melanotan II. 1 line changed; the page grew by 44 bytes.
| Revision 12 — 13:12, 19 Apr 2025 IpamorelinIsold (talk) expand §Pharmacology 3,650 bytes ±0 | Revision 13 — 08:36, 11 May 2025 Peptide_Pete (talk) expand §Documented harms 3,694 bytes +44 | ||
|---|---|---|---|
| 7 | | Related approved compound = [[Bremelanotide]] (MC4R-directed) | 7 | | Related approved compound = [[Bremelanotide]] (MC4R-directed) |
| 8 | }} | 8 | }} |
| + | 9 | {{medical|talk=Unapproved-compound notice}} | |
| 9 | 10 | ||
| 10 | '''Melanotan II''' is a synthetic cyclic analogue of α-melanocyte-stimulating hormone and a non-selective agonist at melanocortin receptors. It is not approved in any jurisdiction and is distributed as a research chemical.{{r|hadley2005}} | 11 | '''Melanotan II''' is a synthetic cyclic analogue of α-melanocyte-stimulating hormone and a non-selective agonist at melanocortin receptors. It is not approved in any jurisdiction and is distributed as a research chemical.{{r|hadley2005}} |